Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the ...
To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Patients who live with CF are faced with a variety of health and lifestyle challenges. When might be the best time to talk ...
Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...
Asian patients with non-cystic fibrosis bronchiectasis had a lower annualized exacerbation rate and less lung function ...
Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...
Dr. Drucy Borowitz helped turn cystic fibrosis from a deadly childhood illness into a treatable condition, giving families ...
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosisTopline data expected in ...
Shares of Arcturus Therapeutics Holdings fell sharply premarket amid fears about patient complications in the wake of a mid-stage trial of a biotech spray treatment for cystic fibrosis that had mixed ...
When I was diagnosed with cystic fibrosis at 43, I thought I was living on borrowed time. Now, at 75, I’ve learned that I am not defined by the odds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback